Dong Qianggang, Feng Jiuxian, Huang Jinsu, Bao Guoliang, Sha Huifang, Gu Weiyong
Shanghai Chest Hospita1, Shanghai Institute of Thoracic Tumors, Shanghai 200030, China.
Zhonghua Zhong Liu Za Zhi. 2002 Mar;24(2):142-6.
To evaluate the effect of vascular endothelia1 growth factor (VEGF) on the hematogenous metastasis of non-small cell lung cancer (NSCLC).
The identification of lung cancer cells in the peripheral blood were carried out by cytological, immunohistocytologica1 and immunofluorecent stains respectively, following isolation of cytokeratin-expressing cells with magnetic activated cell sorting. The quantification of cancer cells in the blood was performed according to the established flow cytometric assay. The plasma VEGF was measured by commercially available ELISA kit.
The lung cancer cells in the blood, showing a remarkable nuclear polymorphism, expressed the epithelial marker cytokeratin and telomerase reverse transcriptase (hTERT). These cells were stained positive by an NSCLC-specific monoclonal antibody S5Al0-2, but negative by antibodies against CD34 and CD45 antigens. Using the flow cytometric assay, 44 cases (28.6%) of l54 NSCLC patients were found to have cancer cells in their blood, with the incidence of positive cases correlated with the stage of disease. The plasma VEGF level was significantly increased in NSCLC patients in comparison with healthy individuals and patients with benign pulmonary diseases. This level was correlated with the stages of disease in patients with adenocarcinoma. In patiens with cancer cells in their blood, a higher level of plasma VEGF was related with an increased number of cancer cells.
The plasma VEGF level is increased in NSCLC patients with approximate1y one fourth to have cancer cells in the peripheral blood. In these patients, increased VEGF level promotes hematogenous tumor metastasis, as indicated by a much higher number of cancer cells in the blood.
评估血管内皮生长因子（VEGF）对非小细胞肺癌（NSCLC）血行转移的影响。
在用磁珠分选法分离出表达细胞角蛋白的细胞后，分别通过细胞学、免疫组织化学和免疫荧光染色对外周血中的肺癌细胞进行鉴定。根据既定的流式细胞术检测法对血液中的癌细胞进行定量分析。采用市售酶联免疫吸附测定（ELISA）试剂盒检测血浆VEGF水平。
血液中的肺癌细胞显示出明显的核多形性，表达上皮标志物细胞角蛋白和端粒酶逆转录酶（hTERT）。这些细胞被NSCLC特异性单克隆抗体S 5A10-2染色呈阳性，但被抗CD34和CD45抗原的抗体染色呈阴性。采用流式细胞术检测法，发现154例NSCLC患者中有44例（28.6%）血液中存在癌细胞，阳性病例的发生率与疾病分期相关。与健康个体和良性肺部疾病患者相比，NSCLC患者的血浆VEGF水平显著升高。该水平与腺癌患者的疾病分期相关。在血液中存在癌细胞的患者中，血浆VEGF水平较高与癌细胞数量增加有关。
NSCLC患者的血浆VEGF水平升高，约四分之一的患者外周血中存在癌细胞。在这些患者中，VEGF水平升高促进血行肿瘤转移，血液中癌细胞数量明显增多表明了这一点。
